Ascentage Pharma Group International, a global biopharmaceutical company, has announced the selection of thirteen studies involving its core assets, including the novel drug olverembatinib (HQP1351) and the investigational Bcl-2 inhibitor lisaftoclax (APG-2575), for presentation at the 2025 European Hematology Association (EHA) Annual Congress. These studies will be featured in an oral presentation, multiple poster presentations, and online publications during the event. The congress, taking place in June 2025, will provide a platform for Ascentage Pharma to present the findings of these studies, which address unmet medical needs in cancer treatment. The presentations will cover various topics, such as the combination of olverembatinib with venetoclax and azacitidine in newly diagnosed Ph+ acute lymphoblastic leukemia, and the efficacy and safety of blinatumomab in newly-diagnosed patients with Ph-positive/negative B-cell acute lymphoblastic leukemia. Additionally, the Embryonic Ectoderm Development (EED) inhibitor APG-5918 will be highlighted for its potent antitumor activity in preclinical T-cell lymphoma models.